Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Iowa for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Iowa only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Iowa (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Bogdan Cherascu (NPI 1588653877)

Field	Value
Entity Type	Individual
Organization	Bogdan Cherascu
Address	202 10th Street Se
City	Cedar Rapids
State	IA
ZIP	52403
Taxonomy	Rheumatology Physician
NPI Enumerated	October 19, 2005

Payer Source	Total Paid
Medicare	$2.4M
Medicaid	$0

Key Findings

This provider’s publicly billed payer mix is effectively single‑payer: total Medicare revenue is $2.4M while Medicaid billing is reported as none, so the practice’s publicly visible revenue footprint depends entirely on Medicare activity rather than dual Medicare/Medicaid flows. Analysts should treat this entity as Medicare‑centric for network, access, and utilization comparisons.

Revenue is highly concentrated in a small set of biologic drug codes: the precomputed top 3 Medicare codes by revenue account for 66.9% of this provider's total Medicare revenue, with J3262 contributing $764K (32.2% of total Medicare revenue), J0129 contributing $526.2K (22.2%), and J1602 contributing $299.4K (12.6%). This concentration indicates that a minority of drug codes drive the majority of Medicare dollars for the provider.

The mix of high‑revenue HCPCS drug codes and infusion/chemotherapy administration CPTs points to an infusion‑centric rheumatology practice. High drug revenues appear under J3262 (152.8K claims, $5 avg paid/claim, $764K revenue), J0129 (15.5K claims, $34 avg paid/claim, $526.2K revenue) and J1602 (29.9K claims, $10 avg paid/claim, $299.4K revenue), and the practice also bills infusion/chemotherapy administration codes such as 96413 (530 claims, $96 avg paid/claim, $50.9K revenue) and 96365 (382 claims, $46 avg paid/claim, $17.6K revenue), consistent with on‑site drug infusion and monitoring services.

On competitive standing, the provider is a national high‑volume outlier for tocilizumab: J3262 ranks #18 of 618 providers nationally (97th percentile; notably above typical national volume for this code), which positions the clinician as a major national participant for that specific biologic. By contrast, J0129 (rank #232 of 1221, 81th percentile; typical, unremarkable volume) and J1602 (rank #159 of 1041, 85th percentile; typical, unremarkable volume) reflect an above‑average but not dominant presence for those biologics.

Beyond the top three drugs, the practice bills other biologics and related infusion agents at material levels — J3111 $196.6K (8.3%), J9312 $191.4K (8.1%), and J1745 $186.7K (7.9%) — indicating a diversified biologic portfolio that extends into therapies commonly used in autoimmune and inflammatory diseases. Several of these codes rank in mid to high percentiles (for example, J1745 ranks #184 of 1352, 86th percentile), signifying meaningful regional/national participation across multiple agents rather than single‑drug dependence.

Lab testing and monitoring are prominent and likely support the biologic/infusion workflow: 85025 appears with 1.2K claims and $9.4K revenue (rank #1940 of 32833, 94th percentile), 82565 with 1.2K claims and $6K revenue (rank #116 of 5066, 98th percentile), and 86140 with 1.2K claims and $6K revenue (rank #195 of 4115, 95th percentile). These high percentiles for routine labs and inflammatory markers suggest in‑office or closely coordinated monitoring resources that align with chronic biologic therapy management.

The presence of infusion‑related add‑on codes like 96415 (205 claims, $21 avg paid/claim, $4.3K revenue) alongside primary infusion codes and multiple parenteral biologic J‑codes indicates the operational capability to provide multi‑hour infusions and extended infusion sessions, consistent with a practice that runs scheduled infusion clinics in addition to standard outpatient visits. This is reinforced by billing for 96413 (therapeutic infusion) at $50.9K and 96365 (initial IV infusion) at $17.6K.

The provider’s NPI was enumerated on 2005-10-19 (~21 years ago), indicating a long tenure in the market; combined with the concentrated biologic revenue and high national percentile for J3262, this suggests an established, infusion‑focused rheumatology practice with a sustained presence in Medicare billing. The absence of Medicaid billing (none) should be considered when assessing Medicaid network access and potential contracting opportunities.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

61 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J3262	Injection, tocilizumab, 1 mg	152,800	$10	$764K
J0129	Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)	15,480	$30	$526.1K
J1602	Injection, golimumab, 1 mg, for intravenous use	29,940	$10	$299.4K
J3111	Injection, romosozumab-aqqg, 1 mg	24,570	$10	$196.6K
J9312	Injection, rituximab, 10 mg	3,190	$60	$191.4K
J1745	Injection, infliximab, excludes biosimilar, 10 mg	7,180	$30	$186.7K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	530	$100	$50.9K
J0897	Injection, denosumab, 1 mg	1,620	$20	$29.2K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	340	$90	$28.8K
96365	The provider administers the initial intravenous infusion of a medication or other substance for a period up to one hour to prevent, treat, or diagnose a condition or disease.	380	$50	$17.6K

Showing 1–10 of 61

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 61 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Iowa Distribution

Bogdan Cherascu — 11 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Iowa

Full comparison — all codes billed, vs. state median

61 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J3262	1	10	35,440	$1	$233.1K
J0129	1	20	5,950	$30	$218.3K
J9312	2	10	3,190	$60	$198.4K
J1602	1	10	13,010	$10	$153.6K
J3111	3	20	12,180	$10	$112K
J1745	2	20	3,460	$30	$92.3K
J0897	112	190	1,920	$20	$74.1K
96413	10	80	210	$90	$24K
99214	859	4,690	100	$70	$14.4K
83970	12	50	40	$40	$8.3K

Showing 1–10 of 61

Related Providers

Other providers that share a Tax Identification Number (TIN) with Bogdan Cherascu, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Thomas Buroker	IA	Medical Oncology Physician	$9.4M	$0
Kyle Alliman	IA	Ophthalmology Physician	$8.7M	$0
Alex Kartvelishvili	IA	Ophthalmology Physician	$8.1M	$0
Paul Boeke	IA	Ophthalmology Physician	$7.1M	$0
Northern Maine Medical Center	ME	Critical Access Hospital	$0	$5.8M
Austin Strohbehn	IA	Retina Specialist (Ophthalmology) Physician	$5.8M	$0
Jeremy Deutsch	KS	Hematology & Oncology Physician	$5.7M	$0
Robert Behrens	IA	Medical Oncology Physician	$5.2M	$0
Physicians' Clinic Of Iowa, PC	IA	Surgery Physician	$0	$4.9M
Matthew Mcknight	IA	Foot & Ankle Surgery Podiatrist	$4.7M	$23.5K

Nearby Providers

Other providers in the same ZIP code as Bogdan Cherascu, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Mercy Medical Center	IA	General Acute Care Hospital	$0	$26.4M
Eastern Iowa Health Center	IA	Family Medicine Physician	$0	$24.5M
Eastern Iowa Health Center	IA	Family Medicine Physician	$0	$18.5M
Eastern Iowa Health Center	IA	General Practice Dentistry	$0	$14.4M
Linn County Emergency Medicine PC	IA	Emergency Medicine Physician	$0	$9.8M
C R Iv Service Inc	IA	Home Infusion Therapy Pharmacy	$0	$5.8M
Mercy Medical Center	IA	Cardiovascular Disease Physician	$0	$5.1M
C R Pharmacy Service Inc	IA	Oxygen Equipment & Supplies (DME)	$0	$2.4M
Vijay Aluri	IA	Rheumatology Physician	$2M	$0
Eastern Iowa Sleep Center, LLC	IA	Sleep Disorder Diagnostic Clinic/Center	$243.7K	$1.6M

Bogdan Cherascu — Billing Profile & Reimbursement Data

Sign up for Bogdan Cherascu — Billing Profile & Reimbursement Data policy alerts

Bogdan Cherascu — Billing Profile & Reimbursement Data

Sign up for Bogdan Cherascu — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References